Sensitivity and Specificity of Nasal Provocation Test in Allergic Rhinitis to House Dust Mites
NCT01485523 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120
Last updated 2013-03-13
Summary
The diagnosis of allergic rhinitis to dust mites is difficult and based on three elements : suggestive symptoms of clinical sensitization to dust mites (rhinitis), the existence of an IgE sensitization defined by skin tests and / or specific IgE positive to mite and finally the presence of mite allergens in the environment where the patient is symptomatic. Unfortunately, the link between symptoms and exposure to dust mites is rarely found and according to in the literature, 30% of rhinitis sensitized to house dust mites did not react during a conventional nasal provocation test (TPNC) to dust mites. Thus, TPNC to dust mite has an interest in the diagnosis of allergic rhinitis to dust mites when there remains a doubt due to the poly sensitization of the patient, or the lack of specific symptoms and / or the variability of the allergic symptoms during the year. However, this test has not been completely validated with a study including a significant number of patients. That's why the investigators plan a prospective single-center comparative open study with the main objective is to determine the sensitivity and specificity of conventional nasal provocation test (TPNC) in 120 patients of 18 to 65 years old with allergic rhinitis sensitized to dust mites and patients with allergic rhinitis not sensitized to dust mites. The investigators secondary objective is to compare the TPNC a faster TPN-called "minute" (60 minutes) and which allow a wider use. If the investigators demonstrate the validity of TPN then it would become the gold standard needed to decide on a desensitisation to mites.
Conditions
- Allergic Rhinitis
Interventions
- OTHER
-
Nasal provocation test
TPNC to dust mite has an interest in the diagnosis of allergic rhinitis to dust mites when there remains a doubt due to the poly sensitization of the patient, or the lack of specific symptoms and / or the variability of the allergic symptoms during the year. However, this test has not completely validated with a study including a significant number of patients. That's why we plan a prospective single-center comparative open study with the main objective is to determine the sensitivity and specificity of conventional nasal provocation test (TPNC) in 120 patients of 18 to 65 years old with allergic rhinitis sensitized to dust mites and patients with allergic rhinitis not sensitized to dust mites. Our secondary objective is to compare the TPNC a faster TPN-called "minute" (60 minutes) and which allow a wider use. If we demonstrate the validity of TPN then it would become the gold standard needed to decide on a desensitisation to mites.
Sponsors & Collaborators
-
University Hospital, Strasbourg, France
lead OTHER
Principal Investigators
-
Jean-Jacques Braun · Hôpitaux Universitaires de Strasbourg
-
Frédéric De Blay · Hôpitaux Universitaires de Strasbourg
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2012-01-31
- Primary Completion
- 2012-08-31
- Completion
- 2012-08-31
Countries
- France
Study Locations
More Related Trials
-
The Prevalence and Clinical Characteristics of Children With Local Allergic Rhinitis
NCT02271620 ·Status: COMPLETED ·Phase: NA
-
Study Evaluating Nasal Symptoms Induced by a Nasal Allergen Challenge (NAC) To House Dust Mite Allergen
NCT01936818 ·Status: COMPLETED
-
Mediators in Nasal Hyperreactivity in Allergic Rhinitis and Chronic Rhinosinusitis
NCT04286542 ·Status: UNKNOWN ·Phase: NA
-
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite
NCT00311051 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy
NCT01014325 ·Status: UNKNOWN ·Phase: PHASE3
-
Evaluation of Nasal Mucosal Permeability in Controls and House Dust Mite Allergic Rhinitis Patients
NCT02461797 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Efficacy and Safety of Levocetirizine to Subjects With Perennial Allergic Rhinitis to House Dust Mites
NCT00521131 ·Status: COMPLETED ·Phase: PHASE4
-
Observation on the Efficacy and Mechanism of SLIT With Dust Mite Allergen for PAR
NCT05570383 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
House Dust Mite SLIT in Elderly Patients
NCT01605760 ·Status: COMPLETED ·Phase: PHASE4
-
Local IgE in Subjects With Allergic or Non-allergic Rhinitis
NCT02810535 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma
NCT00263640 ·Status: COMPLETED ·Phase: PHASE3
-
AZELASTINE/FLUTICASONE (AZE/FLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR)
NCT02238353 ·Status: UNKNOWN ·Phase: PHASE4
-
Repeated Nasal Challenge in Skin Prick-puncture Negative and Intradermal Positive Dust Mite Allergic Rhinitis Patients
NCT01179282 ·Status: COMPLETED ·Phase: NA
-
Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma
NCT01930461 ·Status: COMPLETED ·Phase: PHASE2
-
Comparative Evaluation of Safety and Immune Activity of New Immunotherapeutic Agents for HDM Allergic Rhinitis Patients
NCT05525650 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1
-
House Dust Mite Allergy Trial In Children
NCT04145219 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Efficacy and Safety of Specific Immunotherapy With Modified Allergen Extracts of House Dust Mites
NCT01013116 ·Status: UNKNOWN ·Phase: PHASE3
-
Validation of an Allergic Rhinitis Control Test in Children
NCT03075917 ·Status: RECRUITING ·Phase: NA
-
Effect of Intranasal Anti-IgE Antibodies on IgE Production
NCT03019237 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis
NCT00263549 ·Status: COMPLETED ·Phase: PHASE4
-
Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma
NCT02340130 ·Status: COMPLETED ·Phase: PHASE2
-
the Relationship Between Allergic Rhinitis and the Risk of Symptom in Patients With Mild COVID-19
NCT05753241 ·Status: COMPLETED
-
Assessment of Sublingual Immunotherapy in Children Allergic to House Dust Mites
NCT01052610 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
NCT00574223 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Study of Olopatadine Nasal Spray
NCT00578331 ·Status: COMPLETED ·Phase: PHASE3